乳杆菌 johnsonii JNU3402 通过刺激PGC-1α介导的SIRT1表达来改善与年龄相关的肝功能障碍
Eunjeong Hong1, Garam Yang1, Sejong Oh2
1Department of Biological Sciences, College of Natural Sciences, Chonnam National University, Gwangju, Republic of Korea.
BioFactors (Oxford, England)
|December 5, 2025
概括
牛乳杆菌 johnsonii JNU3402 (LJ3402) 通过减少肝功能障碍和脂质积累来保护衰老的肝脏. 这种益生菌增强了线粒体功能,限制了肝细胞衰老,减缓了与代谢功能障碍相关的脂肪性肝病的进展.
科学领域:
- 老年学是指老年学的学科.
- 肝病学 肝病学是一种肝病学.
- 微生物学 微生物学
背景情况:
- 衰老与代谢疾病密切相关,特别是肝脏异常.
- 饮食诱导的肝肥胖症是一种已知的病症,由Lactobacillus johnsonii JNU3402 (LJ3402) 改善.
- 对于LJ3402对抗与年龄相关的肝脏问题的潜力仍然未被探索.
研究的目的:
- 调查LJ3402对与年龄相关的肝功能障碍和代谢异常的保护作用.
- 阐明LJ3402在衰老肝细胞中的作用背后的分子机制.
主要方法:
- 将LJ3402给24个月大的小鼠.
- 分析肝功能,衰老表型,基因表达和衰老标志物.
- 使用AML12肝细胞进行体外研究,以探索PGC-1α-SIRT1-p53通路.
主要成果:
- 在老年小鼠中,LJ3402的使用减少了肝功能障碍和整体衰老表型.
- LJ3402增加了线粒体功能基因的表达,并减少了肝脏中的衰老标志物.
- 益生菌通过PGC-1α-SIRT1通路抑制p53乙化和活性,减少肝细胞衰老和线粒体功能障碍.
- LJ3402减弱了与年龄相关的肝脂积累,这是MASLD进展的关键方面.
结论:
- LJ3402证明了对与年龄相关的肝功能障碍和代谢异常的保护作用.
- 益生菌机制包括增强PGC-1α-SIRT1-p53通路,从而对抗线粒体功能障碍和肝细胞衰老.
- LJ3402有可能缓解与年龄相关的肝病,包括MASLD.
相关概念视频
01:24Liver Regeneration
4.2K
The liver is an important organ in vertebrates that plays an essential role in metabolism. It is also responsible for storing and redistributing nutrients such as carbohydrates, fats, and vitamins in the body. Additionally, the liver releases bile salts which are critical for digesting food and eliminating toxic metabolites from the body.
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
Cells of Liver
The liver comprises four major types of cells— hepatocytes, stellate, Kupffer, and sinusoidal endothelial cells. The hepatocytes are...
4.2K
01:30Liver Physiology
3.4K
The liver, an essential organ in the human body, performs over 200 vital functions that can be broadly categorized into metabolic, hematological, endocrine regulation, and bile production.
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
Metabolic Regulation:
The liver is the central organ involved in regulating blood composition. It stabilizes blood glucose levels, maintaining them within the range of 70–110 mg/dL. When these levels drop, the liver breaks down glycogen reserves and releases glucose into the bloodstream. It can...
3.4K
01:22Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
01:17Gastritis-II: Pathophysiology
1.1K
Gastritis is marked by disruption of the mucosal barrier that usually protects the stomach tissue from digestive juices and manifests in acute and chronic forms.
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
In acute gastritis, the gastric mucosa becomes swollen and red and undergoes superficial erosion. Superficial ulceration may lead to bleeding.
In chronic gastritis, persistent or repeated insults lead to chronic inflammatory changes and, eventually, thinning or atrophy of the gastric tissue.
Gastritis can stem from various causes, each...
1.1K
01:08Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
241
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
241
01:26Diseases of the Liver and Gallbladder
1.8K
Liver and gallbladder diseases are a significant health concern, with prominent conditions including cirrhosis, hepatitis, non-alcoholic fatty liver disease (NAFLD), and gallstones. Jaundice is a common manifestation of liver and biliary disease.
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
1.8K